• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishDashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI employees
    Legal
    Terms of usePrivacy policyCookie policy

    LifeStance Appoints Dr. Teresa DeLuca to Board of Directors

    3/12/24 9:00:00 AM ET
    $LFST
    Medical/Nursing Services
    Health Care
    Get the next $LFST alert in real time by email

    SCOTTSDALE, Ariz., March 12, 2024 /PRNewswire/ -- LifeStance Health, one of the nation's largest providers of virtual and in-person outpatient mental healthcare, today announced that Dr. Teresa DeLuca has joined the company's board of directors. Dr. DeLuca is a psychiatrist and accomplished physician executive with over 20 years of leadership experience, having held senior executive leadership roles at Magellan Health, Humana and Walgreens, and brings extensive healthcare operations and clinical management expertise to LifeStance's board of directors.

    LifeStance Health Logo (PRNewsfoto/LifeStance Health)

    "Dr. DeLuca's background as a tenured healthcare executive and practicing psychiatrist make her a tremendous addition to our board of directors," said Ken Burdick, Chairman and CEO, LifeStance. "As an organization focused on clinical quality and delivering exceptional patient outcomes, I'm confident that her skills and expertise will be a strong complement to our current board as we continue to expand access to much needed mental healthcare across the country."

    "As the leader in comprehensive, high-quality mental healthcare, LifeStance is truly making a difference in the lives of its patients while also meaningfully addressing the growing mental health crisis," said Dr. DeLuca. "I'm thrilled to join the organization as it continues to advance its mission, and I look forward to working alongside Ken and the board of directors at LifeStance to help even more patients receive the personalized care they need."

    Dr. DeLuca most recently served as Managing Director of Columbia University's NY Life Science Venture, which focused on bringing life sciences research and promising early-stage technologies to market. Previously, she was the Chief Medical Officer at Magellan Health where she spearheaded first-to-market products and technologies, including integrating behavioral health data with pharmacy claims and clinical management. Prior to Magellan Health, Dr. DeLuca served as SVP, Health Solutions at Humana, where she oversaw sales, operations and clinical management. She currently serves on the Board of Directors for Surgery Partners and Rejuveron. Dr. DeLuca received an MBA from Drexel University's LeBow College of Business and her medical degree from Thomas Jefferson University.

    ABOUT LIFESTANCE HEALTH

    Founded in 2017, LifeStance (NASDAQ:LFST) is reimagining mental health. We are one of the nation's largest providers of virtual and in-person outpatient mental healthcare for children, adolescents and adults experiencing a variety of mental health conditions. Our mission is to help people lead healthier, more fulfilling lives by improving access to trusted, affordable and personalized mental healthcare. LifeStance employs approximately 6,600 psychiatrists, advanced practice nurses, psychologists and therapists and operates across 33 states and more than 550 centers. To learn more, please visit www.LifeStance.com. 

    Cision View original content to download multimedia:https://www.prnewswire.com/news-releases/lifestance-appoints-dr-teresa-deluca-to-board-of-directors-302086204.html

    SOURCE LifeStance Health

    Get the next $LFST alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $LFST

    DatePrice TargetRatingAnalyst
    5/27/2025$8.50Neutral → Buy
    UBS
    4/8/2025$9.00Overweight
    KeyBanc Capital Markets
    4/3/2025$8.00Buy
    Canaccord Genuity
    12/16/2024$10.00Neutral → Buy
    Goldman
    1/3/2024$7.00Underweight
    Barclays
    5/15/2023$8.00 → $9.00Outperform → Market Perform
    TD Cowen
    1/6/2023$8.00Equal-Weight → Overweight
    Morgan Stanley
    11/7/2022$7.25Buy
    Jefferies
    More analyst ratings

    $LFST
    SEC Filings

    See more
    • SEC Form 8-K filed by LifeStance Health Group Inc.

      8-K - LifeStance Health Group, Inc. (0001845257) (Filer)

      6/6/25 7:30:16 AM ET
      $LFST
      Medical/Nursing Services
      Health Care
    • LifeStance Health Group Inc. filed SEC Form 8-K: Regulation FD Disclosure

      8-K - LifeStance Health Group, Inc. (0001845257) (Filer)

      5/14/25 9:34:10 AM ET
      $LFST
      Medical/Nursing Services
      Health Care
    • SEC Form 10-Q filed by LifeStance Health Group Inc.

      10-Q - LifeStance Health Group, Inc. (0001845257) (Filer)

      5/7/25 4:42:46 PM ET
      $LFST
      Medical/Nursing Services
      Health Care